Some of Wednesday's midday movers:» Read More
Amgen Inc. rose $1.80 or 1.3 percent, to $139.19. Biogen Idec rose $5.25 or 1.6 percent, to $332.08. Celgene Corp. rose $1.16 or 1.2 percent, to $94.09.
Amgen Inc. rose $1.34 or 1.0 percent, to $138.73. Biogen Idec rose $5.43 or 1.7 percent, to $332.26. Celgene Corp. rose$. 98 or 1.1 percent, to $93.91.
Gilead is already among the 10 best performers in the Nasdaq 100 this year. So can anything slow this behemoth down? If you ask the analysts, it sounds unlikely.
The "Fast Money" traders share their final trades of the day.
Three biotech stocks have plenty of potential, John Schroer of Allianz Global Investors says.
Some of Friday's midday movers:
The dynamics in the market are changing. And Cramer says investors need to change, accordingly.
Aug 27- Roche Holding AG's planned $8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug, but the smaller company's development pipeline may end up giving the Swiss drugmaker a far bigger bang for its buck.
You can’t turn around without hearing the S&P 500 printed 2,000, again, making another record. Can stocks possibly go higher?
*Best Buy tumbles after results, DSW higher. *Digital Ally gains before bell, has tripled this month. Nonetheless, further gains may be a challenge without positive catalysts and amid potential headwinds such as a reduction in Federal Reserve stimulus and a simmering conflict between Ukraine and Russia.
*Digital Ally gains before bell, has tripled this month. NEW YORK, Aug 26- U.S. stock index futures were little changed on Tuesday, with investors finding few reasons to buy after a rally in the previous session that took the S&P 500 above 2,000 for the first time.
Some of Monday's midday movers:
Biotechs rallied after Roche Holding AG agreed to buy InterMune Inc for $8.3 billion in cash, the latest vote of confidence in a sector that many, including Federal Reserve Chair Janet Yellen, are worried is overvalued. InterMune jumped 36 percent to $73.00, with the Nasdaq Biotech index up 2.4 percent.
Apple touched a fresh high Wednesday along with a handful of other companies:
LOS ANGELES, Aug 17- Biotech drug production techniques based on plants, which may prove to be faster, higher yielding and cheaper than current methods using mammalian cells, haven't caught on with the biggest pharmaceutical companies.
*VIX jumps on Russia, Ukraine concerns. NEW YORK, Aug 15- U.S. stocks ended mixed on Friday, paring an earlier selloff sparked by reports of Ukraine shelling a Russian armored column.
U.S. stocks ended the week mixed after news of fresh conflict between Russia and Ukraine.
Take a look at some of Friday's midday movers:
Aug 15- Gilead Sciences Inc said an arbitration panel rejected Roche Holding AG's patent infringement claims related to Gilead's hepatitis C drug, Sovaldi.
Aug 15- Achillion Pharmaceuticals Inc said all patients treated with its experimental hepatitis C drug showed no detectable levels of the virus four weeks after the therapy, sending its shares up 18 percent. Achievement of 100 percent cure rate confirms the competitive profile of NS5A, Wells Fargo Securities analyst Brian Abrahams wrote in a note.